Oblique Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.74M

  • Investors
  • 9

Oblique Therapeutics General Information

Description

Developer of antibody-based drugs designed to treat advanced and metastatic cancer. The company specializes in the research and development of a solid portfolio based on asset generation through advanced antibody technology for severe diseases with a large unmet medical need, focusing on pain and advanced cancer, enabling scientists and researchers to generate novel medicines against any disease-modifying human protein target.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Arvid Wallgrens Backe 20
  • 413 46 Gothenburg
  • Sweden
Primary Industry
Biotechnology
Corporate Office
  • Arvid Wallgrens Backe 20
  • 413 46 Gothenburg
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oblique Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 08-Jul-2022 $2.74M Completed Product Development
6. Later Stage VC 18-Nov-2020 Completed Product Development
5. Grant 19-Dec-2017 Completed Product Development
4. Early Stage VC 01-Dec-2016 Completed Product Development
3. Grant 16-Nov-2016 Completed Product Development
2. Early Stage VC 11-Dec-2015 $1.27M $1.27M Completed Product Development
1. Accelerator/Incubator Completed Startup
To view Oblique Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Oblique Therapeutics Patents

Oblique Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023017149-A1 Thioredoxin 1 antibodies Inactive 13-Aug-2021
GB-202108663-D0 Trpv1 antibodies Inactive 17-Jun-2021
WO-2022219152-A1 Kras antibodies Inactive 16-Apr-2021
GB-202101780-D0 Epitopes and antibodies Inactive 09-Feb-2021
GB-202019522-D0 Epitopes and antibodies Inactive 10-Dec-2020 C07K16/28
To view Oblique Therapeutics’s complete patent history, request access »

Oblique Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oblique Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alsteron Family Office Minority
Granitor Venture Capital Minority
Jinderman & Partners Venture Capital Minority
Sunstone Life Science Ventures Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 9 investors. Get the full list »

Oblique Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Cinda Pharma Goteborg, Sweden 2016

Oblique Therapeutics FAQs

  • When was Oblique Therapeutics founded?

    Oblique Therapeutics was founded in 2015.

  • Where is Oblique Therapeutics headquartered?

    Oblique Therapeutics is headquartered in Gothenburg, Sweden.

  • What is the size of Oblique Therapeutics?

    Oblique Therapeutics has 17 total employees.

  • What industry is Oblique Therapeutics in?

    Oblique Therapeutics’s primary industry is Biotechnology.

  • Is Oblique Therapeutics a private or public company?

    Oblique Therapeutics is a Private company.

  • What is Oblique Therapeutics’s current revenue?

    The current revenue for Oblique Therapeutics is .

  • How much funding has Oblique Therapeutics raised over time?

    Oblique Therapeutics has raised $15.2M.

  • Who are Oblique Therapeutics’s investors?

    Alsteron, Granitor, Jinderman & Partners, Sunstone Life Science Ventures, and are 5 of 9 investors who have invested in Oblique Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process